Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMilionis, H. J.en
dc.contributor.authorElisaf, M. S.en
dc.rightsDefault Licence-
dc.subjectAntihypertensive Agents/*adverse effectsen
dc.subjectFenofibrate/therapeutic useen
dc.subjectHyperlipidemias/blood/*drug therapyen
dc.subjectHypertension/blood/*drug therapyen
dc.subjectHypolipidemic Agents/therapeutic useen
dc.subjectLosartan/adverse effectsen
dc.subjectMiddle Ageden
dc.subjectRisk Factorsen
dc.subjectSodium Chloride Symporter Inhibitors/adverse effectsen
dc.subjectUric Acid/*blooden
dc.titleManagement of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case historiesen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractA number of studies have shown that hyperuricaemia is associated with an increased incidence of coronary heart disease. It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes. Hyperuricaemia is commonly encountered in patients with essential hypertension and is considered as a risk factor for morbidity and mortality associated with hypertension. In addition, lipid abnormalities (mainly hypertriglyceridaemia) are also found more frequently in hypertensive patients than in normotensives. There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule. It is also known that fibric acid derivatives (fibrates) have several beneficial actions in addition to their lipid-lowering capacity. Fenofibrate administration is associated with a uric acid lowering effect. In this respect, we present two patients with hypertension and dyslipidaemia together with elevated serum uric acid levels. We also discuss (in the format of questions and answers) the pathophysiological mechanisms underlying the association of serum uric acid with cardiovascular disease, and we review the relevant literature to justify an evidence-based decision to choose an antihypetensive agent (losartan) or a lipid-lowering drug (fenofibrate) with an additional hypouricaemic effect.en
heal.journalNameCurrent Medical Research and Opinionen
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.

This item is licensed under a Creative Commons License Creative Commons